Pictet Asset Management Holding SA Buys 4,525 Shares of iShares Biotechnology ETF $IBB

Pictet Asset Management Holding SA lifted its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 8.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,475 shares of the financial services provider’s stock after acquiring an additional 4,525 shares during the quarter. Pictet Asset Management Holding SA’s holdings in iShares Biotechnology ETF were worth $12,552,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Bank of America Corp DE lifted its position in iShares Biotechnology ETF by 10.8% during the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares during the period. Royal Bank of Canada boosted its holdings in iShares Biotechnology ETF by 1.0% in the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after purchasing an additional 7,434 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in iShares Biotechnology ETF by 1.3% in the third quarter. Commonwealth Equity Services LLC now owns 139,653 shares of the financial services provider’s stock worth $29,401,000 after purchasing an additional 1,819 shares during the last quarter. Albion Financial Group UT grew its position in iShares Biotechnology ETF by 1.0% in the 3rd quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock worth $25,428,000 after purchasing an additional 1,147 shares during the period. Finally, Cetera Investment Advisers grew its position in iShares Biotechnology ETF by 9.4% in the 1st quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after purchasing an additional 10,994 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Trading Down 2.2%

Shares of IBB opened at $213.43 on Friday. The firm has a fifty day simple moving average of $208.98 and a two-hundred day simple moving average of $186.73. iShares Biotechnology ETF has a 1-year low of $159.68 and a 1-year high of $222.29.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Tuesday, September 15th were paid a $0.0112 dividend. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.0%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.